Mannin Research will be working with Canadian biotech Cyclica to develop novel drugs for COVID-19 , the companies announced this week.
The partnership will use Mannin’s research capacity with Cyclica’s proprietary drug discovery platform. Together, the two will focus on discovering and developing compounds, with COVID-19 being initially prioritized.
Specifically, the partnership will use Mannin’s research and experience with the Tie2 tyrosine kinase receptor, combined with Cyclica’s AI-augmented discovery platforms, Ligand Design and Ligand Express.
Cyclica says that its differentiated platform “opens new opportunities for drug discovery, including multi-targeted and multi-objective drug design, lead optimization, ADMET-property prediction, target deconvolution, and drug repurposing for a wide range of indications.”